TDR’s Top 5 Psychedelic Developments For The Week Of August 29

Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of August 29. Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies.

5. Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. (NEO:CYBN) (OTCMKTS:CLXPF) announced that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder. Based on preclinical data, CYB003 achieved less variability in plasma levels, faster onset of action, and shorter duration of effect. These preclinical data demonstrated that CYB003 has the potential to reduce time and resource burden on patients, providers, and payers, and possibly improve scalability and accessibility of treatment.

Specifically, in multi-species preclinical studies comparing CYB003 with oral psilocybin, data demonstrated:

• a well-tolerated profile following several doses in multiple species that supports repeat dosing;
• a similar in vitro and in vivo pharmacology profile when compared to psilocin, the active naturally occurring psychedelic agent in psilocybin;
• a 50% reduction in variability;
• a 50% dose reduction;
• a 50% shorter time to onset; and,
• nearly double the brain penetration indicating the potential for a less variable treatment response.

4. Top Canadian Official Talks Drug Decriminalization And Psychedelics Reform On U.S. Tour That Involved Oregon Governor Meeting

A top Canadian health official who heads up the country’s efforts to combat addiction visited Colorado, Oregon and Washington State last week to learn about their experiences implementing drug policy reform like broad decriminalization and harm reduction—meeting with the governor of Oregon and psychedelics activists, among others, on a week-long tour.

Liberal MP Carolyn Bennett, who serves as Canada’s minister of mental health and addictions, met with top state officials, activists, harm reduction professionals and law enforcement to discuss how jurisdictions on the other side of the border are addressing drug policy and working to mitigate the overdose crisis.

__________

ARK Invest Psilocybin Drug Sales Projection, Rising 10-Year Estimate

__________

Trade To Black Podcast: Psychedelic Biotech Experiencing Positive Sentiment Change

__________

3. Psychedelic Stocks Flat In Weak Broad Market Conditions

The psychedelic sector finished lower on aggregate this past week. The Horizon Psychedelic Stock Index ETF (PSYK) fell TDR’s Top 5 Psychedelic Developments For The Week Of August 29